Inovio Pharmaceuticals Future Growth
Future criteria checks 2/6
Inovio Pharmaceuticals is forecast to grow earnings and revenue by 36.4% and 75.8% per annum respectively while EPS is expected to grow by 43.9% per annum.
Key information
36.4%
Earnings growth rate
43.9%
EPS growth rate
| Biotechs earnings growth | 37.3% |
| Revenue growth rate | 75.8% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 04 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 17 | -117 | -74 | -27 | 4 |
| 12/31/2025 | 0 | -131 | -126 | -105 | 6 |
| 12/31/2024 | 0 | -127 | -135 | -94 | 6 |
| 6/30/2024 | 1 | -122 | -113 | -112 | N/A |
| 3/31/2024 | 1 | -125 | -117 | -116 | N/A |
| 12/31/2023 | 1 | -135 | -125 | -124 | N/A |
| 9/30/2023 | 1 | -165 | -135 | -134 | N/A |
| 6/30/2023 | 10 | -168 | -173 | -173 | N/A |
| 3/31/2023 | 10 | -241 | -192 | -191 | N/A |
| 12/31/2022 | 10 | -280 | -217 | -216 | N/A |
| 9/30/2022 | 11 | -332 | -219 | -218 | N/A |
| 6/30/2022 | 2 | -355 | -198 | -197 | N/A |
| 3/31/2022 | 2 | -328 | -226 | -225 | N/A |
| 12/31/2021 | 2 | -304 | -217 | -216 | N/A |
| 9/30/2021 | 7 | -221 | -231 | -229 | N/A |
| 6/30/2021 | 6 | -142 | -258 | -257 | N/A |
| 3/31/2021 | 6 | -188 | -207 | -205 | N/A |
| 12/31/2020 | 7 | -166 | -179 | -178 | N/A |
| 9/30/2020 | 2 | -180 | -141 | -140 | N/A |
| 6/30/2020 | 3 | -222 | -94 | -94 | N/A |
| 3/31/2020 | 3 | -123 | -91 | -91 | N/A |
| 12/31/2019 | 4 | -119 | -99 | -98 | N/A |
| 9/30/2019 | 6 | -115 | -103 | -101 | N/A |
| 6/30/2019 | 7 | -117 | -100 | -98 | N/A |
| 3/31/2019 | 32 | -94 | -95 | -93 | N/A |
| 12/31/2018 | 30 | -97 | -76 | -74 | N/A |
| 9/30/2018 | 37 | -86 | -72 | -70 | N/A |
| 6/30/2018 | 37 | -95 | -68 | -63 | N/A |
| 3/31/2018 | 33 | -97 | N/A | -61 | N/A |
| 12/31/2017 | 42 | -88 | N/A | -63 | N/A |
| 9/30/2017 | 42 | -93 | N/A | -64 | N/A |
| 6/30/2017 | 52 | -80 | N/A | -65 | N/A |
| 3/31/2017 | 38 | -89 | N/A | -62 | N/A |
| 12/31/2016 | 35 | -74 | N/A | -63 | N/A |
| 9/30/2016 | 33 | -65 | N/A | -54 | N/A |
| 6/30/2016 | 44 | -39 | N/A | -20 | N/A |
| 3/31/2016 | 44 | -27 | N/A | -16 | N/A |
| 12/31/2015 | 41 | -29 | N/A | -12 | N/A |
| 9/30/2015 | 37 | -19 | N/A | -14 | N/A |
| 6/30/2015 | 15 | -31 | N/A | -37 | N/A |
| 3/31/2015 | 13 | -36 | N/A | -36 | N/A |
| 12/31/2014 | 10 | -36 | N/A | -30 | N/A |
| 9/30/2014 | 10 | -44 | N/A | -21 | N/A |
| 6/30/2014 | 17 | -68 | N/A | -19 | N/A |
| 3/31/2014 | 14 | -68 | N/A | -16 | N/A |
| 12/31/2013 | 13 | -66 | N/A | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0A43 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0A43 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0A43 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0A43's revenue (75.8% per year) is forecast to grow faster than the UK market (3.6% per year).
High Growth Revenue: 0A43's revenue (75.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0A43's Return on Equity is forecast to be high in 3 years time